SUNNYVALE, Calif., Oct. 29 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, announced today that 40 accepted abstracts highlighting the use of the CyberKnife Robotic Radiosurgery System will be presented as posters and presentations at the 52nd Annual Meeting of the American Society for Radiation Oncology (ASTRO), taking place in San Diego from October 31-November 4.
Presentations related to CyberKnife radiosurgery cover a growing array of clinical indications including prostate, intracranial, head and neck, lung, renal, spine and optic, as well as technical presentations including two breast cancer studies and a cost-effectiveness analysis for pancreatic cancer. Additionally, three abstracts from ongoing Accuray-sponsored clinical studies will be presented, which include the inoperable lung cancer study, and the two prostate cancer studies.
Two talks on the use of CyberKnife radiosurgery for the treatment of prostate cancer will be presented on Tuesday, November 2 beginning at 11:45 a.m. PT:
- Robert Meier, M.D., radiation oncologist and medical director for the Swedish Cancer Institute of Northwest Hospital in Seattle, will present a study on quality of life outcomes titled, "Stereotactic Radiotherapy for Organ-confined Prostate Cancer: Early Toxicity and Quality of Life Outcomes from a Multi-institutional Trial."
- Alan J. Katz, M.D., radiation oncologist for Flushing Radiation Oncology and CyberKnife of Long Island in New York, will present a study titled, "Quality of Life and Efficacy for Stereotactic Body Radiotherapy for Treatment of Organ Confined Prostate Cancer." This study assessed the efficacy and toxicity of stereotactic radiosurgery for patients with organ-confined prostate cancer.
Accuray will be exhib